Evaxion A (EVAX) Total Current Liabilities (2019 - 2025)
Evaxion A's (EVAX) quarterly Total Current Liabilities came in at $4.3 million in Q4 2025, down 2.54% YoY from $4.4 million in Q4 2024, and down 20.01% on a QoQ basis from $5.3 million in Q2 2025.
Evaxion A (EVAX) Total Current Liabilities (2019 - 2025) Analysis & Trends
Evaxion A (EVAX) has 7 years of Total Current Liabilities data on file, last reported at $4.3 million in Q4 2025.
- Quarterly Total Current Liabilities fell 2.54% year-over-year to $4.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.3 million (down 2.54% YoY) and the FY2025 annual result came in at $4.3 million, down 2.54% from the prior year.
- Total Current Liabilities declined to $4.3 million in Q4 2025, from $5.3 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $7.1 million in Q4 2023 to a low of $3.8 million in Q4 2022.
- A 5-year average of $4.7 million and a median of $4.4 million in 2024 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2023 — Total Current Liabilities jumped 88.3% — and 2024, when it plunged 38.34%.
- Tracing EVAX's Total Current Liabilities over 5 years: stood at $4.3 million in 2021, then fell by 12.98% to $3.8 million in 2022, then jumped by 88.3% to $7.1 million in 2023, then sank by 38.34% to $4.4 million in 2024, then retreated by 2.54% to $4.3 million in 2025.
- The last three Total Current Liabilities figures came in at $4.3 million (Q4 2025), $5.3 million (Q2 2025), and $4.4 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.61 Bn | 131.75 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 65.28 Bn | 60.09 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 59.14 Bn | 54.00 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 42.13 Bn | 37.03 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.83 Bn | 28.52 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.07 Bn | 9.68 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.54 Bn | 26.38 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 630.93 Mn |
| 10 | Evaxion A | 27.52 Mn | 27.52 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.26 Mn |
| Jun 30, 2025 | 5.32 Mn |
| Dec 31, 2024 | 4.37 Mn |
| Jun 30, 2024 | 3.82 Mn |
| Dec 31, 2023 | 7.08 Mn |
| Jun 30, 2023 | 4.05 Mn |
| Dec 31, 2022 | 3.76 Mn |
| Jun 30, 2022 | 4.41 Mn |
| Mar 31, 2022 | 4.69 Mn |
| Dec 31, 2021 | 4.32 Mn |
| Sep 30, 2021 | 3.92 Mn |
| Jun 30, 2021 | 4.80 Mn |
| Mar 31, 2021 | 6.02 Mn |
| Dec 31, 2020 | 4.93 Mn |
| Dec 31, 2019 | 1.72 Mn |